Clinical Trials on β Thalassemia Major in Hungary

Total 33 results

Novartis Pharmaceuticals

Completed

Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload

Myelodysplastic Syndromes | Beta-Thalassemia

Hungary
Domonkos Trásy

Completed

Continuous Central Venous Oxygen Saturation Assisted Intraoperative Hemodynamic Management

Postoperative Complications | Major Abdominal Surgery | Perioperative Fluid Management | Perioperative Haemodynamic Monitoring | Perioperative Vasopressor Requirement | Postoperative Organ Function

Hungary
Janssen Research & Development, LLC

Completed

A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms

Major Depressive Disorder

Ukraine, Bulgaria, Romania, Russian Federation, Hungary, Moldova, Republic of
Institut de Recherches Internationales Servier
ADIR Association

Completed

Efficacy and Safety of S 47445 Versus Placebo as Adjunctive Treatment in Depressed Patients Not Fully Recovered From Depressive Symptoms With a Current Antidepressant Treatment

Major Depressive Disorder

Bulgaria, Czechia, Finland, Hungary, Russian Federation, Slovakia, Ukraine
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

United States, Spain, Hungary, South Africa, Croatia, France, Poland, India, Canada, Sweden, Malaysia
Intra-Cellular Therapies, Inc.

Completed

Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Major Depressive Disorder

United States, Bulgaria, Czechia, Slovakia, Hungary, India
Eli Lilly and Company

Completed

Early Versus Delayed Switch in Medication in Patients With Major Depressive Disorder

Major Depressive Disorder

Denmark, France, Greece, Hungary, Italy, Netherlands, Romania, Slovenia, Spain, Sweden, Turkey
AstraZeneca
Targacept Inc.

Completed

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

Depression | Major Depressive Disorder

Sweden, Czech Republic, Poland, Germany, Estonia, Latvia, Lithuania, Finland, France, Hungary
Shire

Completed

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States, Germany, Sweden, Poland, South Africa, Belgium, Czechia, Estonia, Finland, Hungary, Romania
Naurex, Inc, an affiliate of Allergan plc

Terminated

Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)

Depressive Disorder, Major

Slovakia, Poland, Hungary, Japan, Russian Federation
AbbVie

Completed

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

Major Depressive Disorder

United States, Bulgaria, Estonia, Germany, Hungary, Ukraine, United Kingdom
Intra-Cellular Therapies, Inc.

Enrolling by invitation

An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Major Depressive Disorder

United States, Bulgaria, Czechia, Slovakia, Germany, Hungary, Poland, Finland, India, Korea, Republic of, Sweden
AstraZeneca
Targacept Inc.

Completed

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.

Major Depressive Disorder

Croatia, Brazil, Bulgaria, France, Poland, Russian Federation, South Africa, Hungary, Romania, Ukraine, Argentina, Chile, Slovakia, Colombia, Germany, Serbia, Spain
Alkermes, Inc.

Completed

A Long-Term Safety Study of ALKS 5461

Major Depressive Disorder

United States, Canada, Germany, Puerto Rico, Bulgaria, Australia, Poland, Hungary
Shire

Terminated

SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

Major Depressive Disorder

United States, Spain, Germany, Puerto Rico, Canada, Estonia, South Africa, Czechia, Finland, Chile, Hungary, Mexico, Poland, Romania
H. Lundbeck A/S

Completed

Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age

Depressive Disorder, Major

Spain, Hungary, Russian Federation, Bulgaria, Estonia, France, Germany, Italy, Latvia, Poland, Serbia, South Africa, United Kingdom
AstraZeneca

Completed

Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients (RUBY)

Major Depressive Disorder | Treatment Resistant Depression

Bulgaria, Italy, United Kingdom, Germany, Hungary, Romania, Austria, Belgium, Denmark, Portugal, Slovakia, Australia, Spain
Sunovion

Completed

A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia

Insomnia | Major Depressive Disorder

France, Poland, Russian Federation, United Kingdom, Austria, Hungary, Croatia, Romania, Serbia, Ukraine
Janssen-Cilag Ltd.

Active, not recruiting

A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment (ESCAPE-LTE)

Depressive Disorder, Major

Taiwan, Turkey, Malaysia, Germany, Czechia, Korea, Republic of, Poland, Hungary, Argentina, Belgium, Bulgaria, Finland, Greece, South Africa
Naurex, Inc, an affiliate of Allergan plc

Terminated

Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)

Depressive Disorder, Major

United States, Poland, Hungary, Japan, Slovakia
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, Germany, Poland, Hungary, Slovakia
H. Lundbeck A/S

Terminated

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

Depressive Disorder, Major

United States, Korea, Republic of, Hungary, Poland, Spain, Serbia, Estonia, Bulgaria, Latvia, Russian Federation, Ukraine, Canada, Colombia, France, Germany, Israel, Italy, Mexico, South Africa, United Kingdom
Janssen Research & Development, LLC

Completed

54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide (Aspire I)

Depressive Disorder, Major

United States, Korea, Republic of, Malaysia, Taiwan, Bulgaria, Spain, Hungary, Germany, Estonia, South Africa, Slovakia
Boehringer Ingelheim

Completed

A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression

Depressive Disorder, Major

Spain, United States, Canada, Germany, Japan, Argentina, Hungary, France, Australia, Bulgaria, Czechia, Poland, Russian Federation, Slovakia
Janssen Research & Development, LLC

Completed

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

Depressive Disorder, Major

United States, France, Italy, Spain, Hungary, Belgium, Brazil, Bulgaria, Poland
H. Lundbeck A/S
Takeda

Completed

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)

Depressive Disorder, Major

United States, Bulgaria, Canada, Colombia, Estonia, France, Germany, Hungary, Italy, Korea, Republic of, Latvia, Mexico, Poland, Russian Federation, Serbia, South Africa, Spain, Ukraine, United Kingdom
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial) (Polaris)

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, Russian Federation, Hungary, Romania, Ukraine, Canada, Germany
Janssen-Cilag International NV

Completed

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)

Depressive Disorder, Major

Israel, Hungary, Korea, Republic of, Taiwan, Portugal, Turkey, Germany, Malaysia, Denmark, Bulgaria, Czechia, Belgium, Poland, Brazil, Netherlands, Argentina, Finland, Greece, South Africa, Austria, Kazakhstan, Norway, Sweden, United...
H. Lundbeck A/S
Takeda

Completed

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)

Depressive Disorder, Major

Korea, Republic of, United States, Hungary, Poland, Spain, Serbia, Estonia, Bulgaria, Mexico, Russian Federation, Ukraine, Canada, Colombia, France, Germany, Israel, Italy, Latvia, South Africa
Janssen Research & Development, LLC

Recruiting

A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT)

Depressive Disorder, Major

United States, Korea, Republic of, Taiwan, Slovakia, Spain, Bulgaria, Poland, Belgium, Argentina, Czechia, Hungary, South Africa, Sweden, Italy, France, Australia, China, Brazil, Portugal
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial) (Orion)

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, France, Poland, Russian Federation, Romania, Ukraine, Germany, Hungary, Slovakia, Serbia, Canada
Janssen Research & Development, LLC

Recruiting

A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy (VENTURA-1)

Anhedonia | Depressive Disorder, Major

United States, Spain, Bulgaria, Italy, Poland, Belgium, Argentina, Czechia, Hungary, Sweden, Brazil, Australia, Portugal
Novartis Pharmaceuticals

Recruiting

CINC424A2X01B Rollover Protocol

Acute Myeloid Leukemia | Primary Myelofibrosis | Polycythemia Vera | Thalassemia | Graft Versus Host Disease

Korea, Republic of, Italy, Belgium, Japan, Germany, Australia, Bulgaria, Chile, China, Denmark, Greece, Hungary, Israel, Lebanon, Poland, Portugal, Russian Federation, Slovakia, South Africa, Spain, Sweden, Thailand, India, Mexico, Turkey, Fran...

Clinical Trials on β Thalassemia Major in Hungary

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations